[Evaluation of ventricular function in patients treated with mitoxantrone and 4'-epidoxorubicin].
Serial assessment of ventricular function by means of radionuclide angiography was performed in previously untreated patients with lymphoproliferative diseases who received either 4'epidoxorubicin or mitoxantrone for longer than 6 months. No changes were observed in left ventricular function in patients received mitoxantrone at doses ranged 90 to 165 mg (mean 113 mg). Three patients (7%) in 4'epidoxorubicin group showed less than or equal to 10% drop in left ventricular ejection, but without clinical manifestations. The doses in this group were 420 to 810 mg (mean 610 mg). We felt that patients without high-risk factors (radiotherapy to mediastinum or previously anthracycline therapy) could be treated with high doses of both drugs and that radionuclide angiography is a useful method for monitoring cardiotoxicity of antineoplastic drugs.
Avilés
A
A
Departamento de Hematología, Centro Médico Nacional I.M.S.S., México, D.F.
Díaz-Maqueo
J C
JC
Arévila-Ceballos
N
N
García Fernández
R
R
López-Vancell
D
D
Torras
V
V
D009202:Cardiomyopathies / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000503:physiopathology; D015251:Epirubicin / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy; D008942:Mitoxantrone / Q000009:adverse effects* / Q000494:pharmacology; D011877:Radionuclide Imaging; D013318:Stroke Volume / Q000187:drug effects*
D015251:Epirubicin; D008942:Mitoxantrone
Valoración de la función ventricular en pacientes tratados con mitoxantrone y 4'epidoxorubicina.